Influence of severe heart failure to function andmolecular biological parameters of catabolism in the human Diaphragm and peripheral skeletal muscle

Completed

• Conditions: I50.14

• Registration Number: DRKS00009848
• Lead Sponsor: Herzzentrum Leipzig GmbHUniversitätsklinik für Kardiologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-01-05
• Study Completion: 2018-03-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

inclusion criteria Group A:
- age 40 – 70 years
- Restricted left ventricular pump function LVEF> 35% on the basis of ischemic cardiomyopathy (ICM) and restricted resting cardiac output (CI> 2.4 L / min / m²)
- or restricted maximal oxygen uptake (VO2max> 17 ml / min / m²)
- Duration of heart failure> 1 year
- Maximum of individual heart failure therapy
- Heart team decision to LVAD Implantation
inclusion criteria Group B:
- age 40 – 70 years
- Restricted left ventricular pump function LVEF> 35% on the basis of dilatiative cardiomyopathy (DCM) and restricted resting cardiac output (CI> 2.4 L / min / m²)
- or restricted maximal oxygen uptake (VO2max> 17 ml / min / m²)
- Duration of heart failure> 1 year
- Maximum of individual heart failure therapy
- Heart team decision to LVAD Implantation
inclusion criteria Group C:
- age 40 - 70 years
- coronary heart disease with indication for elective, coronary artery bypass surgery
- normal LV pumping function LVEF> 50%
- stable clinical situation (no cardiac decompensation within the last 6 months)

Exclusion Criteria

· Mechanical ventilation within the last 3 months
· FEV1 <70% of the norm and / or therapy with
a antagonists, ß-mimetics or
inhaled corticosteroids for the treatment of a lung disease
· Pulmonary fibrosis
· elevated diaphragm in the ultrasound or X-ray diagnosis or known paresis of the phrenic nerve
· renal insufficiency CKD stage 4 and 5, i.e. GFR <30ml / min / 1.73m and / or dialysis
· Acute renal failure
· Treatment with immunosuppressive agents
· Hepatic insufficiency Child-Pugh B and C
· Higher grade ventricular arrhythmias (Lown IV b)
· Acute myocardial infarction (less than three months)
· Decompensated Vitium cordis
· Age <40 years and> 70 years
· Pregnancy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expression of catabolic E3 ligase MuRF1 at the time of sampling

Secondary Outcome Measures

Name	Time	Method
in vitro measurements of the muscle protein (poly ubiquitination of proteins, the proteasome activity, fiber typing in the muscle samples and<br>Measurement of the force development of individual muscle fibers)